CompletedPhase 1NCT03829436
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tempest Therapeutics
- Principal Investigator
- Robert Stagg, PharmDTempest Therapeutics
- Intervention
- Part 1 TPST-1120(drug)
- Enrollment
- 38 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2022
Study locations (11)
- University of California - San Francisco, San Francisco, California, United States
- Miami Cancer Institute, Miami, Florida, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
- Columbia University Medical Center, New York, New York, United States
- Carolina BioOncology Institute, Huntersville, North Carolina, United States
- Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
- University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
- Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
- Sarah Cannon Research Institute - TN, Nashville, Tennessee, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03829436 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
- RECRUITINGPHASE1, PHASE2NCT07239596Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomSuzhou Suncadia Biopharmaceuticals Co., Ltd.
See all trials for Acquired cystic disease-associated renal cell carcinoma →